title: Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals?
authors.affiliation: Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
authors.forename: S D
authors.initials: SD
authors.lastname: Rencher
authors.forename: K S
authors.initials: KS
authors.lastname: Slobod
authors.forename: D H
authors.initials: DH
authors.lastname: Dawson
authors.forename: T D
authors.initials: TD
authors.lastname: Lockey
authors.forename: J L
authors.initials: JL
authors.lastname: Hurwitz
mesh_terms: D016915:AIDS Vaccines / Q000235:genetics / Q000276:immunology*; D000595:Amino Acid Sequence; D015686:Gene Products, env / Q000235:genetics* / Q000276:immunology*; D015752:Genes, env; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D015497:HIV-1 / Q000235:genetics* / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D015686:Gene Products, env; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments